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Table 1
Donor Demographics and Outcomes
Initial
Clearance
N¼15
Not Initially
Cleared
N¼47
Males 8 53% 23 49%
Age median (range) 47 (22-66) 49 (20-72)
Family
Single Donor Family 14 93% 38 81%
Multi Donor Family 1 7% 9 19%
Type
Haplo-identical 3 20% 11 23%
Identical 12 80% 36 77%
Foreign Born 1 7% 13 28%
Donated
Yes 13 87% 31 66%
Ineligible but donated 0 4
Ineligible for PBSC 1 2
No 2 13% 16 34%
Ineligible & Deferred 0 7
More suitable donor 2 2
Recipient delay 0 3
Incomplete clearance 0 2
Change in protocol 0 1
Lab abnormalities 0 1
Product
PBSC 4 31% 25 81%
BM 2 15% 4 13%
MD requested 1 2
Per NMDP 1 2
Lymphocytes 6 46% 1 3%
Combination 1 (PB and BM) 8% 1 (PB and
Lymph)
3%
End Eligibility
Eligible and donated 13 87% 27 57%
Ineligible and donated 0 4 9%
Eligible and did not donate 2 13% 5 11%
Ineligible and did not
donate
0 8 17%
Incomplete Eligibility 0 3 6%
Abbreviations: PBSC e Peripheral Blood Stem Cells; BM e Bone Marrow
Table 2
Additional Evaluations
Abnormal Consult Further Testing
EKG 15 13 3
Pits 5 5 4
LFTs 15 10 9
X-Ray 2 2 1
Urinalysis 10 4 8
Other 8
Abbreviations: EKG e Electrocardiogram; Pits e Platelets, LFTs e Liver
Function Tests, Neuro e Neurology
Abstracts / Biol Blood Marrow Transplant 21 (2015) S240eS265 S261Conclusions: 1) The process of donor clearance has become
more complex and resource demanding. 2) Care should be
taken in selecting donors for screening to avoid unnecessary
added costs to the transplant.369
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Background: Late cytomegalovirus (CMV) disease occurs in
about 6% of patients (R+ or D+/R-) who survive the ﬁrst threemonths after HCT. We have previously identiﬁed steroid
treatment after day 100 and CMV viremia before and after
day 100 as risk factors for late CMV disease. Little is known,
however, about the epidemiology and risk factors of
recurrent late CMV disease. The objectives of this study were
to describe the incidence, clinical characteristics, outcome,
and risk factors for the development of recurrent late CMV
disease.
Methods: We retrospectively analyzed medical records of
117 HCT patients, who developed CMV disease more than
100 days after their ﬁrst allogeneic HCT between 2001 and
2011.We evaluated all CMV disease events occurring be-
tween the ﬁrst late CMV disease and 2 years after HCT. Late
CMV diseasewas considered recurrent if it occurred at least 6
weeks after the ﬁrst late CMV disease.
Results: Among 117 patients with late CMV disease, 31
(26%) patients died within 6 weeks of diagnosis. Twelve of
the eighty-six (14%) surviving patients developed a sec-
ond late CMV disease event. Nine (75%) of the second late
CMV disease cases were observed in the same organ,
while three (25%) occurred in a different organ. There
were 6 (50%) cases of gastrointestinal (GI) disease, 5 (42%)
cases of pneumonia, and 1 (8%) episode of retinitis. Sec-
ond late CMV disease episodes occurred at a median of
147 days [range 52-351] after the ﬁrst late CMV disease
and 374 days [range 212-679] after HCT. In addition, there
were 4 cases of third late CMV disease (3 pneumonia
and 1 GI).
All of the patients were receiving systemic immunosup-
pressive therapies at the time they developed recurrent late
CMV disease. Nine of these twelve patients were undergoing
weekly surveillance for viremia by PCR testing after their ﬁrst
late CMV disease event. Two patients developed CMV disease
while receiving preemptive therapy for viremia. Three pa-
tients had low-level viremia below the threshold for starting
treatment. However, four (33%) of the recurrent late CMV
disease events (2 pneumonia, 2 GI) developed in the absence
of viremia.
Two (17%) of the 12 patients with recurrent late CMV
disease died within 6 weeks of their diagnosis; one addi-
tional patient died shortly after developing a third episode of
CMV disease, and the remaining 9 patients survived at least
to two years after HCT.
Conclusions: These data demonstrate that recurrent late
CMV disease is not a rare event after allogeneic HCT. Patients
who remain on systemic immunosuppressive therapy after a
ﬁrst episode of late CMV disease seem to be at particularly
high risk for recurrence. While preemptive treatment of
viremia might prevent some of these events, one-third of the
cases developed in the absence of viremia including 2 cases
of CMV pneumonia. Further study is warranted to prevent
the morbidity and mortality associated with this late
complication of HCT.TRANSPLANT DATA MANAGEMENT370
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